Immutep (IMMP) highlights robust enrolment in TACTI-004 Phase III trial

Rhea-AI Filing Summary

Immutep Limited submitted a Form 6-K to provide investors with an accompanying report on its clinical development activities. The filing mainly serves as a cover document for an exhibit rather than a detailed operational or financial update.

The attached exhibit, titled “Immutep Announces Strong Operational Progress in Global TACTI-004 (KEYNOTE-F91) Phase III and Enrolment Continues at Robust Pace,” signals that the company is highlighting progress and ongoing patient enrolment in its global TACTI-004 (KEYNOTE-F91) Phase III trial.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Date as December 16, 2025

Commission File Number 001-35428

IMMUTEP LIMITED

(Exact Name as Specified in its Charter)

N/A

(Translation of Registrant’s Name)

Level 32, Australia Square

264 George Street, Sydney

NSW 2000, Australia

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒   Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐   No ☒

If “Yes” is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable.

EXHIBIT INDEX

Exhibit		Description of Exhibit
99.1		Immutep Announces Strong Operational Progress in Global TACTI-004 (KEYNOTE-F91) Phase III and Enrolment Continues at Robust Pace

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: December 16, 2025

IMMUTEP LIMITED
By:		/s/ Marc Voigt
Name:		Marc Voigt
Title:		Chief Executive Officer

FAQ

What does Immutep Limited (IMMP) report in this Form 6-K?

Immutep uses this Form 6-K to furnish an exhibit highlighting clinical trial activity. The exhibit headline refers to strong operational progress and robust enrolment in the global TACTI-004 (KEYNOTE-F91) Phase III study.

What is the key focus of Immutep’s TACTI-004 (KEYNOTE-F91) update?

The focus is operational progress and patient enrolment in the global TACTI-004 (KEYNOTE-F91) Phase III trial. The exhibit title notes strong operational progress and that enrolment continues at a robust pace.

Does this Immutep (IMMP) Form 6-K include financial results?

No financial results are presented in the excerpt. The Form 6-K mainly transmits an exhibit about clinical trial progress for the TACTI-004 (KEYNOTE-F91) Phase III study, rather than earnings or balance sheet information.

Which Immutep document describes TACTI-004 Phase III trial progress?

Exhibit 99.1 attached to the Form 6-K is titled “Immutep Announces Strong Operational Progress in Global TACTI-004 (KEYNOTE-F91) Phase III and Enrolment Continues at Robust Pace,” indicating it contains the detailed trial update.

Who signed Immutep Limited’s Form 6-K related to TACTI-004?

The Form 6-K was signed by Marc Voigt, who is identified as Immutep Limited’s Chief Executive Officer. His signature indicates the company’s authorization of this submission regarding the attached clinical trial progress exhibit.